Early treatment with deferoxamine limits myocardial ischemic/reperfusion injury
about
Mitochondria-targeted agents: Future perspectives of mitochondrial pharmaceutics in cardiovascular diseasesIron-mediated cardiovascular injury.Desferoxamine and ethyl-3,4-dihydroxybenzoate protect myocardium by activating NOS and generating mitochondrial ROS.Lipophilic siderophores of Mycobacterium tuberculosis prevent cardiac reperfusion injury.Reduction in mitochondrial iron alleviates cardiac damage during injuryPossible association of a reduction in cardiovascular events with blood donationOxidative modification by low levels of HOOH can transform myoglobin to an oxidase.Effect of intravenous administration of antioxidants alone and in combination on myocardial reperfusion injury in an experimental pig model.Cellular iron metabolism in health and disease.Chelation and determination of labile iron in primary hepatocytes by pyridinone fluorescent probesLow molecular weight iron and the oxygen paradox in isolated rat hearts.The formation of free radicals by cardiac myocytes under oxidative stress and the effects of electron-donating drugs.Protection by deferoxamine from endothelial injury: a possible link with inhibition of intracellular xanthine oxidase.Detection of small subendocardial infarction using speckle tracking echocardiography in a rat model.Influence of postischemic administration of oxyradical antagonists on ischemic injury to rabbit skeletal muscle.Association between renal iron accumulation and renal interstitial fibrosis in a rat model of chronic kidney disease.Myocardial reperfusion injury and oxidative stress: Therapeutic opportunities
P2860
Q26866951-0ADB56A9-ABEF-4DDF-821A-D4A25815057AQ33687605-54DFC5B5-689B-4CFD-9567-DBD071552033Q34450007-00105AB3-F589-4F16-A05C-7FCAD4F1E06DQ36068269-F1B27FBA-B7A6-4FB0-AE8A-08B91C58C9C8Q36636071-EE8BBE1C-6AD0-4207-A536-2B225752058AQ36847223-012AEFC5-283F-4B47-9BEF-8AA57A95FB32Q37576810-740FE514-3925-4CAC-A736-E76518860834Q37672725-51C2AA73-3212-40F2-AEE0-B2CB6FCA682FQ37783194-01E7C1FC-392C-4213-8709-32DE5E32F301Q39738784-753871B3-51EF-4F68-AAA5-D54B257071C7Q41021290-555100A7-656D-4B20-A497-BDD114D0C04AQ42862221-8FD5F270-5D13-4552-9C99-FF7762678EFDQ45178321-9873B931-5693-46D7-B2BB-49C17629FF18Q48591830-A45C355F-0B6F-4824-92FE-C74949E31FBFQ50753261-FDC1D595-0282-43E3-8E51-CC9AA82E1040Q52965953-02AD0D09-55ED-4CF2-99B4-6C816C158E99Q57821349-842695EB-3594-4668-B6C4-38FB2939E5E8
P2860
Early treatment with deferoxamine limits myocardial ischemic/reperfusion injury
description
1989 nî lūn-bûn
@nan
1989 թուականին հրատարակուած գիտական յօդուած
@hyw
1989 թվականին հրատարակված գիտական հոդված
@hy
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
name
Early treatment with deferoxamine limits myocardial ischemic/reperfusion injury
@ast
Early treatment with deferoxamine limits myocardial ischemic/reperfusion injury
@en
Early treatment with deferoxamine limits myocardial ischemic/reperfusion injury
@nl
type
label
Early treatment with deferoxamine limits myocardial ischemic/reperfusion injury
@ast
Early treatment with deferoxamine limits myocardial ischemic/reperfusion injury
@en
Early treatment with deferoxamine limits myocardial ischemic/reperfusion injury
@nl
prefLabel
Early treatment with deferoxamine limits myocardial ischemic/reperfusion injury
@ast
Early treatment with deferoxamine limits myocardial ischemic/reperfusion injury
@en
Early treatment with deferoxamine limits myocardial ischemic/reperfusion injury
@nl
P2093
P1476
Early treatment with deferoxamine limits myocardial ischemic/reperfusion injury
@en
P2093
K Przyklenk
R A Kloner
P356
10.1016/0891-5849(89)90099-3
P407
P577
1989-01-01T00:00:00Z